BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017;7:e015735. [PMID: 28676480 DOI: 10.1136/bmjopen-2016-015735] [Cited by in Crossref: 134] [Cited by in F6Publishing: 117] [Article Influence: 26.8] [Reference Citation Analysis]
Number Citing Articles
1 Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai C, Floyd T, Al-aly Z. Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney International 2018;94:567-81. [DOI: 10.1016/j.kint.2018.04.011] [Cited by in Crossref: 212] [Cited by in F6Publishing: 172] [Article Influence: 53.0] [Reference Citation Analysis]
2 Kawamura K, Ichikado K, Ichiyasu H, Anan K, Yasuda Y, Suga M, Sakagami T. Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience. BMC Pulm Med 2019;19:113. [PMID: 31238929 DOI: 10.1186/s12890-019-0880-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Sutton SS, Magagnoli J, Cummings T, Hardin JW. The Association between the Use of Proton Pump Inhibitors and the Risk of Hypomagnesemia in a National Cohort of Veteran Patients with HIV. J Int Assoc Provid AIDS Care 2019;18:2325958218821652. [PMID: 30798693 DOI: 10.1177/2325958218821652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Yang YSH, Chang HW, Lin IH, Chien LN, Wu MJ, Liu YR, Chu PG, Xie G, Dong F, Jia W, Chang VHS, Yen Y. Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats. Sci Rep 2020;10:866. [PMID: 31964941 DOI: 10.1038/s41598-020-57612-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
5 Srivastava SK, Clergeaud G, Andresen TL, Boisen A. Micromotors for drug delivery in vivo: The road ahead. Advanced Drug Delivery Reviews 2019;138:41-55. [DOI: 10.1016/j.addr.2018.09.005] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 17.0] [Reference Citation Analysis]
6 Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS Investigators. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology 2019;157:682-691.e2. [PMID: 31152740 DOI: 10.1053/j.gastro.2019.05.056] [Cited by in Crossref: 138] [Cited by in F6Publishing: 112] [Article Influence: 46.0] [Reference Citation Analysis]
7 Lazzerini PE, Cartocci A, Qu YS, Saponara S, Furini S, Fusi F, Fabris F, Gamberucci A, El-Sherif N, Cevenini G, Pettini F, Laghi-Pasini F, Acampa M, Bertolozzi I, Capecchi PL, Lazaro D, Boutjdir M. Proton Pump Inhibitors Directly Block hERG-Potassium Channel and Independently Increase the Risk of QTc Prolongation in a Large Cohort of US Veterans. Circ Arrhythm Electrophysiol 2021;14:e010042. [PMID: 34143643 DOI: 10.1161/CIRCEP.121.010042] [Reference Citation Analysis]
8 Ikeji C, Williams A, Hennawi G, Brandt NJ. Patient and Provider Perspectives on Deprescribing Proton Pump Inhibitors. J Gerontol Nurs 2019;45:9-17. [PMID: 31560071 DOI: 10.3928/00989134-20190912-03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Lee HJ, Lee H, Oh SH, Park J, Park S, Jeon JS, Noh H, Han DC, Kwon SH. Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients. PLoS One 2018;13:e0203878. [PMID: 30212538 DOI: 10.1371/journal.pone.0203878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Chen G, Ning LJ, Qin Y, Zhao B, Mei D, Li XM. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data. J Gastroenterol Hepatol 2021;36:156-62. [PMID: 32542684 DOI: 10.1111/jgh.15151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
11 Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney Int 2018;93:741-52. [PMID: 29241622 DOI: 10.1016/j.kint.2017.08.033] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
12 Kua CH, Yeo CYY, Tan PC, Char CWT, Tan CWY, Mak V, Leong IY, Lee SWH. Association of Deprescribing With Reduction in Mortality and Hospitalization: A Pragmatic Stepped-Wedge Cluster-Randomized Controlled Trial. J Am Med Dir Assoc 2021;22:82-89.e3. [PMID: 32423694 DOI: 10.1016/j.jamda.2020.03.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Moayyedi P, Lewis MA. Proton Pump Inhibitors and Dementia: Deciphering the Data. American Journal of Gastroenterology 2017;112:1809-11. [DOI: 10.1038/ajg.2017.415] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
14 Spechler SJ. Proton Pump Inhibitors: What the Internist Needs to Know. Med Clin North Am 2019;103:1-14. [PMID: 30466666 DOI: 10.1016/j.mcna.2018.08.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
15 Hart E, Dunn TE, Feuerstein S, Jacobs DM. Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retrospective Cohort Study. Pharmacotherapy 2019;39:443-53. [PMID: 30779194 DOI: 10.1002/phar.2235] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 8.3] [Reference Citation Analysis]
16 Khoma O, Falk SE, Burton L, Van der Wall H, Falk GL. Gastro-Oesophageal Reflux and Aspiration: Does Laparoscopic Fundoplication Significantly Decrease Pulmonary Aspiration? Lung 2018;196:491-6. [PMID: 29804143 DOI: 10.1007/s00408-018-0128-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
17 Wang YT, Tsai MC, Wang YH, Wei JC. Association Between Proton Pump Inhibitors and Asthma: A Population-Based Cohort Study. Front Pharmacol 2020;11:607. [PMID: 32457614 DOI: 10.3389/fphar.2020.00607] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Tick H, Nielsen A, Pelletier KR, Bonakdar R, Simmons S, Glick R, Ratner E, Lemmon RL, Wayne P, Zador V; Pain Task Force of the Academic Consortium for Integrative Medicine and Health. Evidence-Based Nonpharmacologic Strategies for Comprehensive Pain Care: The Consortium Pain Task Force White Paper. Explore (NY) 2018;14:177-211. [PMID: 29735382 DOI: 10.1016/j.explore.2018.02.001] [Cited by in Crossref: 112] [Cited by in F6Publishing: 85] [Article Influence: 28.0] [Reference Citation Analysis]
19 Lindley RI. Stroke Prevention in the Very Elderly. Stroke 2018;49:796-802. [DOI: 10.1161/strokeaha.117.017952] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
20 Horvath A, Stadlbauer V. [Proton Pump Inhibitors and their Microbiome-Mediated Side Effects]. Zentralbl Chir 2021;146:165-9. [PMID: 33327006 DOI: 10.1055/a-1312-7587] [Reference Citation Analysis]
21 El Rouby N, Lima JJ, Johnson JA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin Drug Metab Toxicol. 2018;14:447-460. [PMID: 29620484 DOI: 10.1080/17425255.2018.1461835] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 12.0] [Reference Citation Analysis]
22 Moayyedi P. How to advise patients on the risk of chronic proton pump inhibitor therapy. Curr Opin Gastroenterol 2020;36:317-22. [PMID: 32487851 DOI: 10.1097/MOG.0000000000000641] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
23 McKinnon BJ, Hawkshaw MJ, Sataloff RT. Proton Pump Inhibitor-related Mortality: Let Us Not Be Dead Wrong. J Voice 2017;31:519. [PMID: 28867109 DOI: 10.1016/j.jvoice.2017.08.012] [Reference Citation Analysis]
24 Baik SH, Fung K, Mcdonald CJ. The Mortality Risk of Proton Pump Inhibitors in 1.9 Million US Seniors: An Extended Cox Survival Analysis. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.01.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Al-Aly Z. Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodium-Glucose Cotransporter-2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes. J Am Heart Assoc 2021;10:e020237. [PMID: 34013739 DOI: 10.1161/JAHA.120.020237] [Reference Citation Analysis]
26 Kurlander JE, Rubenstein JH, Richardson CR, Krein SL, De Vries R, Zikmund-Fisher BJ, Yang YX, Laine L, Weissman A, Saini SD. Physicians' Perceptions of Proton Pump Inhibitor Risks and Recommendations to Discontinue: A National Survey. Am J Gastroenterol 2020;115:689-96. [PMID: 32091419 DOI: 10.14309/ajg.0000000000000558] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
27 Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Ther Adv Drug Saf 2019;10:2042098618809927. [PMID: 31019676 DOI: 10.1177/2042098618809927] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 9.5] [Reference Citation Analysis]
28 Corsonello A, Lattanzio F. Cardiovascular and non-cardiovascular concerns with proton pump inhibitors: Are they safe? Trends in Cardiovascular Medicine 2019;29:353-60. [DOI: 10.1016/j.tcm.2018.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
29 Cai M, Xie Y, Bowe B, Gibson AK, Zayed MA, Li T, Al-Aly Z. Temporal Trends in Incidence Rates of Lower Extremity Amputation and Associated Risk Factors Among Patients Using Veterans Health Administration Services From 2008 to 2018. JAMA Netw Open 2021;4:e2033953. [PMID: 33481033 DOI: 10.1001/jamanetworkopen.2020.33953] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
30 Bowe B, Artimovich E, Xie Y, Yan Y, Cai M, Al-Aly Z. The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: a modelling study. BMJ Glob Health 2020;5:e002063. [PMID: 32341805 DOI: 10.1136/bmjgh-2019-002063] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
31 Mohamed Ibrahim O, Al Mazrouei N, Al Meslamani AZ, Kassem AB, El-Bassiouny NA, Mohammed Ebaed SB, Ibrahim RM. Assessment of a new strategy for catalyzing deprescribing in community pharmacies. J Am Pharm Assoc (2003) 2021:S1544-3191(21)00373-3. [PMID: 34580032 DOI: 10.1016/j.japh.2021.09.003] [Reference Citation Analysis]
32 Fitzgerald RC, Corley DA. Will a Proton Pump Inhibitor and an Aspirin Keep the Doctor Away for Patients With Barrett's Esophagus? Gastroenterology 2019;156:1228-31. [PMID: 30849313 DOI: 10.1053/j.gastro.2019.03.001] [Reference Citation Analysis]
33 Anstey MH, Litton E, Palmer RN, Neppalli S, Tan BJ, Hawkins DJ, Krishnamurthy RB, Jacques A, Sonawane RV, Chapman AR, Norman R. Clinical and economic benefits of de-escalating stress ulcer prophylaxis therapy in the intensive care unit: A quality improvement study. Anaesth Intensive Care 2019;47:503-9. [DOI: 10.1177/0310057x19860972] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
34 Bowe B, Xie Y, Li T, Yan Y, Xian H, Al-Aly Z. Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD. J Am Soc Nephrol. 2018;29:218-230. [PMID: 28935655 DOI: 10.1681/asn.2017030253] [Cited by in Crossref: 111] [Cited by in F6Publishing: 55] [Article Influence: 22.2] [Reference Citation Analysis]
35 Lazzerini PE, Bertolozzi I, Finizola F, Acampa M, Natale M, Vanni F, Fulceri R, Gamberucci A, Rossi M, Giabbani B, Caselli M, Lamberti I, Cevenini G, Laghi-Pasini F, Capecchi PL. Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes. Front Pharmacol 2018;9:363. [PMID: 29731714 DOI: 10.3389/fphar.2018.00363] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
36 Roberts G, Pegoli M, Grzeskowiak L, Benger S, Forbes H, Hunt K, Jafari S, Koeper I, McDonald C, Nguyen H, Rawther K, Taeuber L, Tran E, Vu P, Wisdom A, Russell P. Hospital admission as a deprescribing triage point for patients discharged to Residential Aged Care Facilities. Age Ageing 2021:afab082. [PMID: 34036308 DOI: 10.1093/ageing/afab082] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Ben-Eltriki M, Green CJ, Maclure M, Musini V, Bassett KL, Wright JM. Do proton pump inhibitors increase mortality? A systematic review and in-depth analysis of the evidence. Pharmacol Res Perspect 2020;8:e00651. [PMID: 32996701 DOI: 10.1002/prp2.651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Robson J, Laborda T, Fitzgerald S, Andersen J, Peterson K, O'Gorman M, Guthery S, Bennett-Murphy L. Avoidant/Restrictive Food Intake Disorder in Diet-treated Children With Eosinophilic Esophagitis. J Pediatr Gastroenterol Nutr 2019;69:57-60. [PMID: 30889128 DOI: 10.1097/MPG.0000000000002323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
39 Srinutta T, Chewcharat A, Takkavatakarn K, Praditpornsilpa K, Eiam-Ong S, Jaber BL, Susantitaphong P. Proton pump inhibitors and hypomagnesemia: A meta-analysis of observational studies. Medicine (Baltimore). 2019;98:e17788. [PMID: 31689852 DOI: 10.1097/md.0000000000017788] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
40 Calvo-henríquez C, Ruano-ravina A, Vaamonde P, Lattomus K, Sebio A, Fernández-rodríguez R, Martin-martin C. Translation and Validation of the Reflux Symptom Index to Spanish. Journal of Voice 2019;33:807.e1-5. [DOI: 10.1016/j.jvoice.2018.04.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
41 Kua CH, Mak VSL, Huey Lee SW. Health Outcomes of Deprescribing Interventions Among Older Residents in Nursing Homes: A Systematic Review and Meta-analysis. J Am Med Dir Assoc 2019;20:362-372.e11. [PMID: 30581126 DOI: 10.1016/j.jamda.2018.10.026] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 10.8] [Reference Citation Analysis]
42 Henriquez DDCA, Caram-Deelder C, le Cessie S, Zwart JJ, van Roosmalen JJM, Eikenboom JCJ, So-Osman C, van de Watering LMG, Zwaginga JJ, Koopman-van Gemert AWMM, Bloemenkamp KWM, van der Bom JG; TeMpOH-1 Research Group. Association of Timing of Plasma Transfusion With Adverse Maternal Outcomes in Women With Persistent Postpartum Hemorrhage. JAMA Netw Open 2019;2:e1915628. [PMID: 31730187 DOI: 10.1001/jamanetworkopen.2019.15628] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
43 Shi L, Zhang D. Proton Pump Inhibitor Use Before ICU Admission Is Not Associated With Mortality of Critically Ill Patients. J Clin Pharmacol 2020;60:860-6. [PMID: 32043627 DOI: 10.1002/jcph.1585] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Avraham O, Biglow M. Implementation of Proton Pump Inhibitor Deprescription Protocol in Geriatric Residents. Ann Pharmacother 2018;52:747-53. [PMID: 29473423 DOI: 10.1177/1060028018759747] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
45 Cetin H, Sun J, Almqvist C, Reichardt B, Tomschik M, Zimprich F, Fang F, Ingre C. No association between proton pump inhibitor use and ALS risk: a nationwide nested case-control study. Sci Rep 2020;10:13371. [PMID: 32770128 DOI: 10.1038/s41598-020-70373-8] [Reference Citation Analysis]
46 Franchi C, Mannucci PM, Nobili A, Ardoino I. Use and prescription appropriateness of drugs for peptic ulcer and gastrooesophageal reflux disease in hospitalized older people. Eur J Clin Pharmacol 2020;76:459-65. [PMID: 31853593 DOI: 10.1007/s00228-019-02815-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
47 Kaneko H, Itoh H, Kamiya K, Morita K, Sugimoto T, Konishi M, Kiriyama H, Kamon T, Fujiu K, Michihata N, Jo T, Takeda N, Morita H, Yasunaga H, Komuro I. Acute-phase initiation of cardiac rehabilitation and clinical outcomes in hospitalized patients for acute heart failure. Int J Cardiol 2021;340:36-41. [PMID: 34454966 DOI: 10.1016/j.ijcard.2021.08.041] [Reference Citation Analysis]
48 Al-qaisi MT, Kahn A, Crowell MD, Burdick GE, Vela MF, Ramirez FC. Do recent reports about the adverse effects of proton pump inhibitors change providers’ prescription practice? Diseases of the Esophagus 2018;31. [DOI: 10.1093/dote/doy042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Horvath A, Rainer F, Bashir M, Leber B, Schmerboeck B, Klymiuk I, Groselj-Strele A, Durdevic M, Freedberg DE, Abrams JA, Fickert P, Stiegler P, Stadlbauer V. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. Sci Rep. 2019;9:12000. [PMID: 31427714 DOI: 10.1038/s41598-019-48352-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
50 Valette S, Dory A, Gourieux B, Weber JC. [Evaluation of the implantation of a de-prescribing process for proton pump inhibitor (PPI) using an algorithm within an internal medicine department]. Rev Med Interne 2021;42:535-40. [PMID: 33323294 DOI: 10.1016/j.revmed.2020.11.014] [Reference Citation Analysis]
51 Brown JP, Tazare JR, Williamson E, Mansfield KE, Evans SJ, Tomlinson LA, Bhaskaran K, Smeeth L, Wing K, Douglas IJ. Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study. Br J Clin Pharmacol 2021;87:3150-61. [PMID: 33393677 DOI: 10.1111/bcp.14728] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Savarino V, Marabotto E, Furnari M, Zingone F, Zentilin P, Savarino E. Latest insights into the hot question of proton pump inhibitor safety - a narrative review. Dig Liver Dis. 2020;52:842-852. [PMID: 32513631 DOI: 10.1016/j.dld.2020.04.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
53 Cetin H, Wurm R, Reichardt B, Tomschik M, Silvaieh S, Parvizi T, König T, Erber A, Schernhammer E, Stamm T, Stögmann E. Increased risk of death associated with the use of proton-pump inhibitors in patients with dementia and controls - a pharmacoepidemiological claims data analysis. Eur J Neurol 2020;27:1422-8. [PMID: 32281706 DOI: 10.1111/ene.14252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Duncan DR, Mitchell PD, Larson K, McSweeney ME, Rosen RL. Association of Proton Pump Inhibitors With Hospitalization Risk in Children With Oropharyngeal Dysphagia. JAMA Otolaryngol Head Neck Surg 2018;144:1116-24. [PMID: 30325987 DOI: 10.1001/jamaoto.2018.1919] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
55 Wu J, Dickinson S, Elgebaly Z, Blogg S, Heaney A, Soo Y, Daniels B, Weekes L. Impact of NPS MedicineWise general practitioner education programs and Choosing Wisely Australia recommendations on prescribing of proton pump inhibitors in Australia. BMC Fam Pract 2020;21:85. [PMID: 32386520 DOI: 10.1186/s12875-020-01158-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:851-66. [PMID: 32172363 DOI: 10.1007/s00228-020-02854-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
57 Naunton M, Peterson GM, Deeks LS, Young H, Kosari S. We have had a gutful: The need for deprescribing proton pump inhibitors. J Clin Pharm Ther 2018;43:65-72. [PMID: 28895169 DOI: 10.1111/jcpt.12613] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
58 Esteban‐fernández de Ávila B, Angsantikul P, Li J, Gao W, Zhang L, Wang J. Micromotors Go In Vivo: From Test Tubes to Live Animals. Adv Funct Mater 2018;28:1705640. [DOI: 10.1002/adfm.201705640] [Cited by in Crossref: 63] [Cited by in F6Publishing: 51] [Article Influence: 12.6] [Reference Citation Analysis]
59 Mizokami Y, Yamamoto T, Atarashi H, Yamashita T, Akao M, Ikeda T, Koretsune Y, Okumura K, Shimizu W, Tsutsui H, Toyoda K, Hirayama A, Yasaka M, Yamaguchi T, Teramukai S, Kimura T, Kaburagi J, Takita A, Inoue H. Current status of proton pump inhibitor use in Japanese elderly patients with non-valvular atrial fibrillation: A subanalysis of the ANAFIE Registry. PLoS One 2020;15:e0240859. [PMID: 33151969 DOI: 10.1371/journal.pone.0240859] [Reference Citation Analysis]
60 De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, Hsiang JC. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol 2019; 25(33): 4933-4944 [PMID: 31543684 DOI: 10.3748/wjg.v25.i33.4933] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
61 Wijarnpreecha K, Thongprayoon C, Chesdachai S, Panjawatanana P, Ungprasert P, Cheungpasitporn W. Associations of Proton-Pump Inhibitors and H2 Receptor Antagonists with Chronic Kidney Disease: A Meta-Analysis. Dig Dis Sci 2017;62:2821-7. [DOI: 10.1007/s10620-017-4725-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
62 Conte C, Bourrel R, Despas F, Lapeyre-Mestre M. Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas? A cohort study based on the French health insurance database in the Midi-Pyrénées region. Fundam Clin Pharmacol 2019;33:327-38. [PMID: 30625254 DOI: 10.1111/fcp.12436] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
63 Cai M, Bowe B, Xie Y, Al-Aly Z. Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs. BMJ Open 2021;11:e047369. [PMID: 34400452 DOI: 10.1136/bmjopen-2020-047369] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Douwes RM, Gomes-Neto AW, Eisenga MF, Van Loon E, Schutten JC, Gans ROB, Naesens M, van den Berg E, Sprangers B, Berger SP, Navis G, Blokzijl H, Meijers B, Bakker SJL, Kuypers D. The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study. PLoS Med 2020;17:e1003140. [PMID: 32542023 DOI: 10.1371/journal.pmed.1003140] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Tebala GD. The Emperor's New Clothes: a Critical Appraisal of Evidence-based Medicine. Int J Med Sci. 2018;15:1397-1405. [PMID: 30275768 DOI: 10.7150/ijms.25869] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
66 Meyer MJ, Seitz T, Brockmöller J, Tzvetkov MV. Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine. PLoS One 2017;12:e0189521. [PMID: 29236753 DOI: 10.1371/journal.pone.0189521] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
67 Kanno T, Moayyedi P. Who Needs Gastroprotection in 2020? Curr Treat Options Gastroenterol 2020;:1-17. [PMID: 33199955 DOI: 10.1007/s11938-020-00316-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
68 Xie Y, Bowe B, Yan Y, Xian H, Li T, Al-Aly Z. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 2019;365:l1580. [PMID: 31147311 DOI: 10.1136/bmj.l1580] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 21.3] [Reference Citation Analysis]
69 Shiratori Y, Ikeya T, Ishii N, Yamamoto K, Honda T, Hasatani K, Yoshida N, Nishida T, Sumiyoshi T, Kiyotoki S, Arai M, Niikura R. Association between the chronic use of gastric acid suppressants and high-risk colorectal polyps. JGH Open 2021;5:371-6. [PMID: 33732884 DOI: 10.1002/jgh3.12503] [Reference Citation Analysis]
70 Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat Commun 2021;12:6571. [PMID: 34772922 DOI: 10.1038/s41467-021-26513-3] [Reference Citation Analysis]
71 Manolis AA, Manolis TA, Melita H, Katsiki N, Manolis AS. Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries? Eur J Intern Med 2020;72:15-26. [PMID: 31796246 DOI: 10.1016/j.ejim.2019.11.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
72 Chiu L, Shen M, Lo CH, Chiu N, Chen A, Shin HJ, Prsic EH, Hur C, Chow R, Lebwohl B. Effect of famotidine on hospitalized patients with COVID-19: A systematic review and meta-analysis. PLoS One 2021;16:e0259514. [PMID: 34735523 DOI: 10.1371/journal.pone.0259514] [Reference Citation Analysis]
73 Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018;53:172-177. [PMID: 29477057 DOI: 10.1016/j.canep.2018.02.004] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 7.5] [Reference Citation Analysis]
74 Malhotra K, Katsanos AH, Bilal M, Ishfaq MF, Goyal N, Tsivgoulis G. Cerebrovascular Outcomes With Proton Pump Inhibitors and Thienopyridines: A Systematic Review and Meta-Analysis. Stroke 2018;49:312-8. [PMID: 29339434 DOI: 10.1161/STROKEAHA.117.019166] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
75 Falk GL. Risk awareness for proton pump inhibition: Necessitates review of recommendations in anti-reflux disease. Surgeon 2020;18:189-90. [PMID: 31610985 DOI: 10.1016/j.surge.2019.09.001] [Reference Citation Analysis]
76 Al-aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021;594:259-64. [DOI: 10.1038/s41586-021-03553-9] [Cited by in Crossref: 61] [Cited by in F6Publishing: 70] [Article Influence: 61.0] [Reference Citation Analysis]
77 Chowdhry M, Shah K, Kemper S, Zekan D, Carter W, Mcjunkin B. Proton pump inhibitors not associated with hypomagnesemia, regardless of dose or concomitant diuretic use: PPIs are not associated with hypomagnesemia. Journal of Gastroenterology and Hepatology 2018;33:1717-21. [DOI: 10.1111/jgh.14141] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
78 Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton Pump Inhibitors: Review of Emerging Concerns. Mayo Clin Proc. 2018;93:240-246. [PMID: 29406201 DOI: 10.1016/j.mayocp.2017.10.022] [Cited by in Crossref: 79] [Cited by in F6Publishing: 63] [Article Influence: 26.3] [Reference Citation Analysis]
79 Rosenberg V, Tzadok R, Chodick G, Kariv R. Proton pump inhibitors long term use-trends and patterns over 15 years of a large health maintenance organization. Pharmacoepidemiol Drug Saf 2021;30:1576-87. [PMID: 34453456 DOI: 10.1002/pds.5352] [Reference Citation Analysis]
80 Brusselaers N, Sadr-Azodi O, Engstrand L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol 2020;55:453-61. [PMID: 31811561 DOI: 10.1007/s00535-019-01652-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
81 Song HJ, Rhew K, Lee YJ, Ha IH. Acid-suppressive agents and survival outcomes in patients with cancer: a systematic review and meta-analysis. Int J Clin Oncol 2021;26:34-50. [PMID: 33089416 DOI: 10.1007/s10147-020-01795-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Garibaldi BT, Wang K, Robinson ML, Zeger SL, Bandeen-Roche K, Wang MC, Alexander GC, Gupta A, Bollinger R, Xu Y. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19. JAMA Netw Open 2021;4:e213071. [PMID: 33760094 DOI: 10.1001/jamanetworkopen.2021.3071] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
83 Xie Y, Bowe B, Maddukuri G, Al-Aly Z. Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study. BMJ 2020;371:m4677. [PMID: 33323357 DOI: 10.1136/bmj.m4677] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
84 Camilo SMP, Almeida ÉCS, Sousa JB, Camilo LP, Etchebehere RM. CHRONIC USE OF PROTON PUMP INHIBITORS AND THE QUANTITY OF G, D, AND ECL CELLS IN THE STOMACH. Arq Bras Cir Dig 2020;33:e1506. [PMID: 32844883 DOI: 10.1590/0102-672020190001e1506] [Reference Citation Analysis]
85 Bowman MH. Peer-Led Education Expedites Deprescribing Proton Pump Inhibitors for Appropriate Veterans. Gastroenterol Nurs 2020;43:218-24. [PMID: 32433431 DOI: 10.1097/SGA.0000000000000479] [Reference Citation Analysis]
86 Rameau A, Andreadis K, Bayoumi A, Kaufman M, Belafsky P. Side Effects of Proton Pump Inhibitors: What are Patients’ Concerns? Journal of Voice 2021;35:809.e15-20. [DOI: 10.1016/j.jvoice.2020.01.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
87 Pittayanon R, Piyachaturawat P, Rerknimitr R, Prueksapanich P, Chaitongrat S, Lertsuwunseri V, Srimahachota S, Mahachai V. Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial. J Gastroenterol Hepatol 2019;34:1517-22. [PMID: 30919492 DOI: 10.1111/jgh.14671] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
88 Targownik L. Discontinuing Long-Term PPI Therapy: Why, With Whom, and How? American Journal of Gastroenterology 2018;113:519-28. [DOI: 10.1038/ajg.2018.29] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
89 Muñoz-torrero JFS, Zamorano J, Rico-martín S, Rivas MD, Bacaicoa MA, Robles R, Sanchez-bacaicoa C, Monreal M. Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease. Atherosclerosis 2020;292:84-9. [DOI: 10.1016/j.atherosclerosis.2019.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
90 Bahat G, Ilhan B, Bay I, Kilic C, Kucukdagli P, Oren MM, Karan MA. Explicit versus implicit evaluation to detect inappropriate medication use in geriatric outpatients. Aging Male 2020;23:179-84. [PMID: 29671705 DOI: 10.1080/13685538.2018.1464552] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
91 Sarnaik MK, Modi S, Pisipati Y, Vaidya S, Syed Gaggatur N, Sange AH, Srinivas N, Sange I. Proton Pump Inhibitors: Exploring Cardiovascular Complications and Prescription Protocol. Cureus 2021;13:e16744. [PMID: 34354892 DOI: 10.7759/cureus.16744] [Reference Citation Analysis]
92 Luetzenberg FS, Jiang N. Practice patterns of reflux medication prescriptions in otolaryngology compared to other specialties. The Laryngoscope 2019;130:321-7. [DOI: 10.1002/lary.27916] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Lanas-gimeno A, Hijos G, Lanas Á. Proton pump inhibitors, adverse events and increased risk of mortality. Expert Opinion on Drug Safety 2019;18:1043-53. [DOI: 10.1080/14740338.2019.1664470] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
94 Xie Y, Bowe B, Gibson AK, McGill JB, Maddukuri G, Al-Aly Z. Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. JAMA Intern Med 2021;181:1043-53. [PMID: 34180939 DOI: 10.1001/jamainternmed.2021.2488] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
95 Xu X, Huo Z, Guo J, Liu H, Qi X, Wu Z. Micromotor-derived composites for biomedicine delivery and other related purposes. Bio-des Manuf 2020;3:133-47. [DOI: 10.1007/s42242-020-00072-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
96 Zarea Gavgani V, Mirzadeh-Qasabeh S, Hanaee J, Hamishehkar H. Calculating reading ease score of patient package inserts in Iran. Drug Healthc Patient Saf 2018;10:9-19. [PMID: 29593437 DOI: 10.2147/DHPS.S150428] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 Brusselaers N, Lagergren J. Maintenance use of non-steroidal anti-inflammatory drugs and risk of gastrointestinal cancer in a nationwide population-based cohort study in Sweden. BMJ Open 2018;8:e021869. [PMID: 29982219 DOI: 10.1136/bmjopen-2018-021869] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
98 Muheim L, Signorell A, Markun S, Chmiel C, Neuner-Jehle S, Blozik E, Ursprung P, Rosemann T, Senn O. Potentially inappropriate proton-pump inhibitor prescription in the general population: a claims-based retrospective time trend analysis. Therap Adv Gastroenterol 2021;14:1756284821998928. [PMID: 33948109 DOI: 10.1177/1756284821998928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
99 Xie Y, Bowe B, Gibson AK, McGill JB, Yan Y, Maddukuri G, Al-Aly Z. Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events. Diabetes Care 2020;43:2785-95. [PMID: 32912850 DOI: 10.2337/dc20-1231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
100 Sing CW, Wong AY, Kiel DP, Cheung EY, Lam JK, Cheung TT, Chan EW, Kung AW, Wong IC, Cheung CL. Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture. J Bone Miner Res 2018;33:1422-34. [PMID: 29744914 DOI: 10.1002/jbmr.3448] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 9.8] [Reference Citation Analysis]
101 Schubert ML. Adverse effects of proton pump inhibitors: fact or fake news? Current Opinion in Gastroenterology 2018;34:451-7. [DOI: 10.1097/mog.0000000000000471] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
102 Li T, Xie Y, Al-Aly Z. The association of proton pump inhibitors and chronic kidney disease: cause or confounding? Curr Opin Nephrol Hypertens 2018;27:182-7. [PMID: 29432214 DOI: 10.1097/MNH.0000000000000406] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
103 Wright DJ, Scott S, Buck J, Bhattacharya D. Role of nurses in supporting proactive deprescribing. Nurs Stand 2019;34:44-50. [PMID: 31468926 DOI: 10.7748/ns.2019.e11249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
104 Gramont B, Bertoletti L, Roy M, Roblin X, Tardy B, Cathébras P. [Use and management of proton pump inhibitors: An observational study]. Therapie 2020;75:649-62. [PMID: 32591130 DOI: 10.1016/j.therap.2020.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil 2018;24:182-96. [PMID: 29605975 DOI: 10.5056/jnm18001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 19.0] [Reference Citation Analysis]
106 Xie Y, Bowe B, Li T, Xian H, Al-Aly Z. Blood urea nitrogen and risk of insulin use among people with diabetes. Diab Vasc Dis Res 2018;15:409-16. [PMID: 29974791 DOI: 10.1177/1479164118785050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
107 Al-Aly Z, Maddukuri G, Xie Y. Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe. Am J Kidney Dis 2020;75:497-507. [PMID: 31606235 DOI: 10.1053/j.ajkd.2019.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
108 Ariel H, Cooke JP. Cardiovascular Risk of Proton Pump Inhibitors. Methodist Debakey Cardiovasc J 2019;15:214-9. [PMID: 31687101 DOI: 10.14797/mdcj-15-3-214] [Reference Citation Analysis]
109 Moulis G, Lapeyre-Mestre M. [Propensity score: Interests, use and limitations. A practical guide for clinicians]. Rev Med Interne 2018;39:805-12. [PMID: 29514739 DOI: 10.1016/j.revmed.2018.02.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
110 Bowe B, Xie Y, Li T, Yan Y, Xian H, Al-Aly Z. Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study. Lancet Planet Health. 2017;1:e267-e276. [PMID: 29851625 DOI: 10.1016/s2542-5196(17)30117-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 35] [Article Influence: 13.0] [Reference Citation Analysis]
111 McCombe PA, Garton FC, Katz M, Wray NR, Henderson RD. What do we know about the variability in survival of patients with amyotrophic lateral sclerosis? Expert Rev Neurother 2020;20:921-41. [PMID: 32569484 DOI: 10.1080/14737175.2020.1785873] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
112 Salvo EM, Ferko NC, Cash SB, Gonzalez A, Kahrilas PJ. Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors. Aliment Pharmacol Ther 2021;54:129-43. [PMID: 34114655 DOI: 10.1111/apt.16407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
113 Kikuchi S, Togo K, Ebata N, Fujii K, Yonemoto N, Abraham L, Katsuno T. A Retrospective Database Study of Gastrointestinal Events and Medical Costs Associated with Nonsteroidal Anti-Inflammatory Drugs in Japanese Patients of Working Age with Osteoarthritis and Chronic Low Back Pain. Pain Med 2021;22:1029-38. [PMID: 33585939 DOI: 10.1093/pm/pnaa421] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Naito Y, Kashiwagi K, Takagi T, Andoh A, Inoue R. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use. Digestion. 2018;97:195-204. [PMID: 29316555 DOI: 10.1159/000481813] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 11.0] [Reference Citation Analysis]
115 Ayyagari S, Tan MC, Liu Y, El-Serag HB, Thrift AP. Use of Acid-Suppressant Medications After Diagnosis Increases Mortality in a Subset of Gastrointestinal Cancer Patients. Dig Dis Sci 2020;65:2691-9. [PMID: 31802383 DOI: 10.1007/s10620-019-05984-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Coyle C, Symonds R, Allan J, Dawson S, Russell S, Smith A, Daff C, Kotze H. Sustained proton pump inhibitor deprescribing among dyspeptic patients in general practice: a return to self-management through a programme of education and alginate rescue therapy. A prospective interventional study. BJGP Open 2019;3:bjgpopen19X101651. [PMID: 31581112 DOI: 10.3399/bjgpopen19X101651] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
117 He Q, Xia B, Meng W, Fan D, Kuo ZC, Huang J, Qin X, Zou H, He Y, Zhang C, Fang S, Pan Y, Yang M, Yuan J. No Associations Between Regular Use of Proton Pump Inhibitors and Risk of All-Cause and Cause-Specific Mortality: A Population-Based Cohort of 0.44 Million Participants. Am J Gastroenterol 2021. [PMID: 34313608 DOI: 10.14309/ajg.0000000000001377] [Reference Citation Analysis]
118 Wilson JA, Stocken DD, Watson GC, Fouweather T, McGlashan J, MacKenzie K, Carding P, Karagama Y, Harries M, Ball S, Khwaja S, Costello D, Wood R, Lecouturier J, O'Hara J. Lansoprazole for persistent throat symptoms in secondary care: the TOPPITS RCT. Health Technol Assess 2021;25:1-118. [PMID: 33492208 DOI: 10.3310/hta25030] [Reference Citation Analysis]
119 Daumas A, Garros E, Mendizabal H, Gayet S, Bernard F, Bagnères D, Demoux A, Rossi P, Villani P, Granel B. Impact d’une évaluation des pratiques professionnelles sur la pertinence des prescriptions d’inhibiteurs de la pompe à protons à l’hôpital. La Revue de Médecine Interne 2018;39:618-26. [DOI: 10.1016/j.revmed.2018.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
120 Rameau A, Lee M, Andreadis K, Sulica L. Perception of Proton Pump Inhibitor Side Effects Among Members of the American Broncho-Esophagological Association. J Voice 2021:S0892-1997(21)00173-9. [PMID: 34154915 DOI: 10.1016/j.jvoice.2021.05.006] [Reference Citation Analysis]
121 Howden CW, Korvick JA, Harinstein L, Weissfeld J, Moayyedi P, Vakil N, Harris MS. Controversies Around Measuring Drug Toxicity: US Food and Drug Administration and Gastrointestinal Perspectives. Gastroenterology 2020;158:22-7. [DOI: 10.1053/j.gastro.2019.10.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Kanno T, Moayyedi P. Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem. Curr Gastroenterol Rep 2019;21:65. [PMID: 31807948 DOI: 10.1007/s11894-019-0732-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
123 Moayyedi P, El-Serag HB. Current Status of Chemoprevention in Barrett's Esophagus. Gastrointest Endosc Clin N Am 2021;31:117-30. [PMID: 33213791 DOI: 10.1016/j.giec.2020.08.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]